Key points from article :
Enhertu’s performance was compared against against trastuzumab emtansine.
As a treatment for HER2-positive metastatic breast cancer. involved around 500 patients.
All patients treated with Enhertu were alive after 12 months (94.1 per cent).
Compared to 85.9 per cent of patients treated with trastuzumab emtansine (T-DM1).
Susan Galbraith, executive vice president of Oncology says "...shift in the treatment of HER2-positive metastatic breast cancer".
Javier Cortes says "Remarkable potential of Enhertu to become the new standard treated for HER2-positive metastatic breast cancer".
Ken Takeshita, global head of R&D at Daiichi Sankyo, said: "...bring Enhertu to patients with previously treated HER2-positive metastatic breast cancer".
The drug is under phase 3 clinical trial and not yet mature.
